NuVasive gets warning letter over spinal implant marketing

03/20/2013 | MassDevice.com (Boston)

The FDA has issued a warning letter to NuVasive over certain marketing language regarding the company's Affix Spinous Process Plate System. NuVasive said in a regulatory filing that it is already beginning to address the issue, and the company stressed to its shareholders that there were no manufacturing problems that needed to be addressed.

View Full Article in:

MassDevice.com (Boston)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA